ALNY:NGS-Alnylam Pharmaceuticals Inc. (USD)

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing

USD 250

Change

-6.45 (-2.52)%

Market Cap

USD 3.92B

Volume

0.91M

Analyst Target

USD 166.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+9.65 (+2.09%)

USD 118.90B
REGN Regeneron Pharmaceuticals Inc

+5.66 (+0.83%)

USD 73.95B
ARGX argenx NV ADR

+1.14 (+0.18%)

USD 40.41B
ONC BeiGene, Ltd.

-1.42 (-0.60%)

USD 25.62B
RPRX Royalty Pharma Plc

-0.26 (-0.79%)

USD 18.65B
SMMT Summit Therapeutics PLC

+0.52 (+2.47%)

USD 17.52B
UTHR United Therapeutics Corporatio..

+7.95 (+2.13%)

USD 15.68B
INCY Incyte Corporation

-1.11 (-1.56%)

USD 14.29B
INSM Insmed Inc

+2.47 (+3.04%)

USD 13.70B
MRNA Moderna Inc

+0.15 (+0.42%)

USD 12.93B

ETFs Containing ALNY

MSGR 6.64 % 0.00 %

N/A

N/A
CURE:XETRA 5.76 % 0.00 %

N/A

N/A
CURG:LSE VanEck Genomics and Healt.. 5.47 % 0.00 %

+0.27 (+1.66%)

USD 5.28M
GNOM Global X Genomics & Biote.. 3.94 % 0.00 %

+0.16 (+1.66%)

USD 0.07B
GNOG:LSE Global X Genomics & Biote.. 3.90 % 0.00 %

+0.09 (+1.66%)

USD 9.83M
BIOT:SW L&G Pharma Breakthrough U.. 3.89 % 0.00 %

N/A

N/A
FBT:LSE First Trust Global Funds .. 3.61 % 0.00 %

+14.90 (+1.66%)

USD 8.65M
FBTU:LSE First Trust Global Funds .. 3.61 % 0.00 %

+0.07 (+1.66%)

USD 8.62M
2B70:F 3.37 % 0.00 %

N/A

N/A
2B70:XETRA 3.37 % 0.00 %

N/A

N/A
IBB iShares Biotechnology ETF 3.21 % 0.47 %

+1.63 (+1.66%)

USD 6.39B
BTEC:SW iShares Nasdaq US Biotech.. 3.20 % 0.00 %

+0.01 (+1.66%)

N/A
IBBQ Invesco Nasdaq Biotechnol.. 3.04 % 0.00 %

+0.22 (+1.66%)

USD 0.04B
CURE:AU ETFS S&P Biotech ETF 2.52 % 0.00 %

-0.16 (1.66%)

USD 0.04B
BIB ProShares Ultra Nasdaq Bi.. 2.42 % 0.95 %

+0.99 (+1.66%)

USD 0.06B
JNDQ:AU BETAJNDQ ETF UNITS 2.14 % 0.00 %

+0.09 (+1.66%)

N/A
EQQJ:SW Invesco NASDAQ Next Gener.. 2.11 % 0.00 %

+0.51 (+1.66%)

N/A
QQQJ Invesco NASDAQ Next Gen 1.. 2.09 % 0.00 %

+0.05 (+1.66%)

USD 0.68B
EQJS:LSE Invesco NASDAQ Next Gener.. 2.09 % 0.00 %

+20.25 (+1.66%)

USD 0.05B
EQQJ:LSE Invesco NASDAQ Next Gener.. 2.02 % 0.00 %

+0.12 (+1.66%)

N/A
HTEC Robo Global® Healthcare .. 1.91 % 0.00 %

+0.32 (+1.66%)

USD 0.05B
EQQJ:XETRA 1.87 % 0.00 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 1.71 % 1.14 %

+3.55 (+1.66%)

USD 0.77B
TMFX Motley Fool Next Index ET.. 1.65 % 0.00 %

-0.30 (1.66%)

USD 0.03B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.36 % 0.00 %

+6.75 (+1.66%)

N/A
THNZ:XETRA 0.87 % 0.00 %

N/A

N/A
ETHO Amplify ETF Trust 0.60 % 0.45 %

+0.13 (+1.66%)

USD 0.18B
BBH VanEck Biotech ETF 0.00 % 0.35 %

+2.18 (+1.66%)

USD 0.40B
FFTY Innovator IBD® 50 ETF 0.00 % 0.80 %

-0.52 (1.66%)

N/A
LABS 0.00 % 0.45 %

N/A

N/A
QRH:CA 0.00 % 1.20 %

N/A

N/A
RBUS 0.00 % 0.30 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+1.66%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.05 (+1.66%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+1.66%)

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

+1.20 (+1.66%)

N/A
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
GERM 0.00 % 0.00 %

N/A

N/A
QQQN 0.00 % 0.00 %

N/A

N/A
XGES:LSE Xtrackers MSCI Genomic He.. 0.00 % 0.00 %

+0.20 (+1.66%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 6.24% 70% C- 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.24% 70% C- 68% D+
Trailing 12 Months  
Capital Gain 67.01% 88% B+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 67.01% 88% B+ 88% B+
Trailing 5 Years  
Capital Gain 87.80% 88% B+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 87.80% 88% B+ 82% B
Average Annual (5 Year Horizon)  
Capital Gain 15.60% 63% D 69% C-
Dividend Return 15.60% 63% D 67% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.31% 88% B+ 65% D
Risk Adjusted Return 55.11% 95% A 80% B-
Market Capitalization 3.92B 99% N/A 97% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 1,081.59 1% 0%
Price / Cash Flow Ratio 335.98 1% 1%
Price/Free Cash Flow Ratio 204.85 1% 2%
Management Effectiveness  
Return on Equity -1,500.66% 5% 2%
Return on Invested Capital -34.83% 67% 29%
Return on Assets -2.92% 92% 46%
Debt to Equity Ratio -462.63% 98% 98%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.